<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567798</url>
  </required_header>
  <id_info>
    <org_study_id>SPL/UP/2017/01</org_study_id>
    <nct_id>NCT03567798</nct_id>
  </id_info>
  <brief_title>Thrombocytopenia Induced by Chemotherapy</brief_title>
  <acronym>papayaleaf</acronym>
  <official_title>A Post Marketing Randomized Placebo Controlled Study to Evaluate the Efficacy of Study Product UPLAT® (Carica Papaya Leaf Extract + Tinospora Cardifolia Extract) in the Cancer Patients With Thrombocytopenia Induced by Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Socrates School Of Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Socrates School Of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of
      Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided
      into [screening visit (visit 1) &gt; baseline and treatment allocation visit (visit 2) &gt;blood
      collection (visit 3); treatment compliance visit (visit 4) &gt; blood collection (visit 5)
      &gt;blood collection (visit 6)&gt;end of study visit (visit 7)].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract), is an orally administered
      dietary supplement for management of thrombocytopenia. Manufactured bySanat Products Ltd.

      Throughout study, it will be designated as product A to maintain study blindness at subject
      end.

      Placebo Throughout study, it will be designated as product B to maintain study blindness at
      subject end.

      Single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of
      Study product in patient with Chemotherapy induced thrombocytopenia. The Study is divided
      into [screening visit (visit 1) &gt; baseline and treatment allocation visit (visit 2) &gt;blood
      collection (visit 3); treatment compliance visit (visit 4) &gt; blood collection (visit 5)
      &gt;blood collection (visit 6)&gt;end of study visit (visit 7)].

      Dose regimen After meeting the inclusion criteria subject will take 4 units daily (2 in
      morning and 2 in evening) for 10 days. Patients will be called on Day5th, 10th and 15thfor
      the Complete blood count (Central lab).

      Total blood loss Approximately 8-12 mL
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Actual">November 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blind, randomized, multicentric placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in the platelet counts from baseline levels to the end of therapy.</measure>
    <time_frame>Day 15</time_frame>
    <description>Increase in the platelet counts from baseline levels to the end
of therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract
Take 4 units daily (2 in morning and 2 in evening) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo
Take 4 units daily (2 in morning and 2 in evening) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>UPLAT</intervention_name>
    <description>Carica papaya leaf Extract + Tinospora cardifolia Extract</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged between 18-55 years.

          2. Subjects must sign with date an informed consent prior to any evaluation and
             participation in the trial.

          3. Patients who were confirmed solid tumour and received at least one cycle of
             chemotherapy prior to screening visit.

          4. Patients with a platelet counts between &gt; 20000 and &lt; 150,000/ml at the time of
             screening.

        Exclusion Criteria:

          1. Planning to receive any type of surgery.

          2. Pregnant or lactating women.

          3. Patients with platelet count less than 20000/ml.

          4. Patients with thrombocytopenia presenting with active bleeding.

          5. Patients who have received blood or blood product transfusion during the current
             illness or during past one week.

          6. Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding
             diathesis.

          7. Participation in another trial with another investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>North East Cancer Centre Hospital and research Institute</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781023</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Not Yet Decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

